Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Minimally Invasive Biopsy Predicting Breast pCR After NAC for Breast Cancer (MIBPBPCR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03789851
Recruitment Status : Recruiting
First Posted : December 31, 2018
Last Update Posted : December 31, 2018
Sponsor:
Information provided by (Responsible Party):
Yongsheng Wang, Shandong Cancer Hospital and Institute

Brief Summary:

Neoadjuvant chemotherapy (NAC) is widely used as an efficient breast cancer treatment. Ideally, a pathological complete remission (pCR) can be achieved. With improvements in molecular typing guided NAC and targeted therapies, there has been dramatic improvement in pCR rates, especially among triple-negative and human epidermal growth factor receptor 2 positive breast cancers. Rates of pCR in these groups of patients can reach 60% or higher. NAC has significantly promoted the loco-regional de-escalating treatment of breast cancer, and the need for breast surgery in NAC cases with pCR has been questioned, especially in patients undergoing breast-conserving surgery with whole breast radiotherapy. The main impediments for potential elimination of breast surgery have been the fact that conventional and functional breast imaging techniques are incapable of accurate prediction of residual disease. However, imaging-guided minimally invasive biopsy (MIB) techniques might have the potential to overcome this impediment.

The investigators design and begin a prospective one-armed clinical study to explore the accuracy of MIB in predicting breast pCR after NAC.


Condition or disease Intervention/treatment Phase
Breast Cancer Device: core needle biopsy Not Applicable

Detailed Description:

In clinical routine surgical treatment follows the neoadjuvant chemotherapy (NAC). However, recent studies have demonstrated that shrinking tumors need less surgical treatment indicating that patients with pCR could potentially be spared of surgery in the future. However, up to now, prediction of pCR after NACT is only moderately accurate. This prospective, monocenter diagnostic trial aims to explore if minimal invasive biopsies (MIB) might overcome this diagnostic challenge.

From June 1st, 2017 to June 15th, 2019 the investigators performed ultrasound-guided multipoint core needle biopsy (CNB) on 50 breast cancer patients after NAC and directly after surgery. To analyse CNB pathologically results were categorized as follows: residual vital tumor cells (invasive, in situ, both, lymphangiosis carcinomatosous) present, (significant parts of) the tumor bed present, neither vital tumor cells nor (significant parts of) the tumor bed (indicating a non representative VAB). The results were compared to those of the pathological examination of surgical specimen.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Minimally Invasive Biopsy Technique Predicting Breast Pathological Complete Respons After Neoadjuvant Chemotherapy for Breast Cancer
Actual Study Start Date : June 1, 2017
Estimated Primary Completion Date : June 15, 2019
Estimated Study Completion Date : June 1, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: core needle biopsy
All patients enrolled in this study received a ultrasound-guided multipoint core needle biopsy after surgery.
Device: core needle biopsy
Because the ultrasound was unable to accurately position the marker clip, I125 coud be placed at the position of the marker clip under the guidance of preoperative mammography. The gamma detector was used to locate the tumor bed to guide the ultrasound-guided multi-point CNB. Ultrasound-guided multipoint CNB was used directly after breast conserving surgery or mastectomy. Centering on the marker clip, the range of 0.5 cm was the first area, and then the range of 0.5 cm was the second area, and so on, until the extent of the expansion reached the long diameter of the original tumor, and 4 pieces were uniformly taken in each area.
Other Name: ultrasound-guided multipoint core needle biopsy




Primary Outcome Measures :
  1. false negative CNB results,reported as the false negative rate (= FNR) [ Time Frame: after breast surgery, up to 2 weeks after CNB ]
    non-detected residual tumor by CNB (=index test) compared to breast surgery (=reference test): FNR = rate of patients with non-detected residual tumor by CNB compared to breast surgery Residual tumor is defined as a positive result; in surgical specimen as well as in CNB.


Secondary Outcome Measures :
  1. negative predictive value (NPV) [ Time Frame: after breast surgery, up to 2 weeks after CNB ]
    The negative predictive value (NPV) will be calculated as the quotient of the number of cases with pCR in CNB and in surgical specimen (= true negative result), divided by the total number of cases with pCR in CNB. Residual tumor is defined as a positive result; in surgical specimen as well as in CNB.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • after full-course neoadjuvant chemotherapy (NAC) according to the NACT protocol
  • with cT1c-cT4a-c tumors
  • after informed consent
  • with breast ultrasound, mammography (and breast MRI where necessary) before and after NACT
  • Clinical / imaging partial or complete response to NAC
  • Any routine breast cancer surgical intervention planned according to guidelines (breast conservation or mastectomy)
  • Residual intramammary target lesion or clip marker is visible in ultrasound and / or mammography
  • Inclusion of only one breast per patient, in bilateral cancer one breast can be included
  • In case of multicentric disease: confirmation of the same tumorbiological subtype defined by immunohistology in at least 2 lesions.

Exclusion Criteria:

  • Palliative or recurrent breast cancer
  • Pregnancy and lactation
  • cT4d stage (inflammatory breast cancer)
  • M1 stages
  • stable disease according to a multimodal assessment of ultrasound, mammography and breast MRI (if available) according to RECIST
  • dislocation of marker (> 10mm distance to the initial lesion)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03789851


Contacts
Layout table for location contacts
Contact: Yong-sheng Wang +86 0531-67626213 wangysh2008@aliyun.com

Locations
Layout table for location information
China
Breast Cancer Center, Shandong Cancer Hospital Affiliated to Shandong University Recruiting
Jinan, China, 250117
Contact: Yong-sheng Wang    +86 676-26213    wangysh2008@aliyun.com   
Sponsors and Collaborators
Shandong Cancer Hospital and Institute

Layout table for additonal information
Responsible Party: Yongsheng Wang, Director of the Breast Cancer Center, Shandong Cancer Hospital and Institute
ClinicalTrials.gov Identifier: NCT03789851     History of Changes
Other Study ID Numbers: MIB001
First Posted: December 31, 2018    Key Record Dates
Last Update Posted: December 31, 2018
Last Verified: December 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases